- Home
- NGNE vs MNTK Comparison
NGNE vs MNTK Comparison
Compare NGNE & MNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- MNTK
- Stock Information
- Founded
- NGNE 2003
- MNTK 1980
- Country
- NGNE United States
- MNTK United States
- Employees
- NGNE N/A
- MNTK N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- MNTK Natural Gas Distribution
- Sector
- NGNE Health Care
- MNTK Utilities
- Exchange
- NGNE Nasdaq
- MNTK Nasdaq
- Market Cap
- NGNE 325.3M
- MNTK 306.2M
- IPO Year
- NGNE N/A
- MNTK 2021
- Fundamental
- Price
- NGNE $18.48
- MNTK $2.15
- Analyst Decision
- NGNE Strong Buy
- MNTK Hold
- Analyst Count
- NGNE 7
- MNTK 3
- Target Price
- NGNE $41.86
- MNTK $3.33
- AVG Volume (30 Days)
- NGNE 110.1K
- MNTK 223.8K
- Earning Date
- NGNE 08-11-2025
- MNTK 08-06-2025
- Dividend Yield
- NGNE N/A
- MNTK N/A
- EPS Growth
- NGNE N/A
- MNTK N/A
- EPS
- NGNE N/A
- MNTK 0.02
- Revenue
- NGNE N/A
- MNTK $181,341,000.00
- Revenue This Year
- NGNE N/A
- MNTK $3.74
- Revenue Next Year
- NGNE N/A
- MNTK $3.88
- P/E Ratio
- NGNE N/A
- MNTK $116.00
- Revenue Growth
- NGNE N/A
- MNTK N/A
- 52 Week Low
- NGNE $6.88
- MNTK $1.68
- 52 Week High
- NGNE $74.49
- MNTK $6.04
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- MNTK 51.51
- Support Level
- NGNE $19.59
- MNTK $1.98
- Resistance Level
- NGNE $20.46
- MNTK $2.26
- Average True Range (ATR)
- NGNE 1.23
- MNTK 0.10
- MACD
- NGNE -0.20
- MNTK 0.03
- Stochastic Oscillator
- NGNE 13.37
- MNTK 72.50
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.